Pfizer (NYSE:PFE) Stock Price Up 1.1%

Shares of Pfizer Inc. (NYSE:PFE) were up 1.1% during mid-day trading on Tuesday . The stock traded as high as $29.14 and last traded at $29.13. Approximately 5,275,507 shares changed hands during trading, a decline of 87% from the average daily volume of 39,272,527 shares. The stock had previously closed at $28.80.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PFE shares. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market cap of $163.76 billion, a P/E ratio of -484.17, a P/E/G ratio of 1.00 and a beta of 0.69. The company’s 50 day simple moving average is $28.76 and its 200 day simple moving average is $27.92.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.81%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is -2,800.00%.

Institutional Investors Weigh In On Pfizer

Large investors have recently made changes to their positions in the stock. Olistico Wealth LLC acquired a new position in Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the second quarter worth $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.